MedTrace Logo

Efavirenz (EFV) Intensification

NCT07193875 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-09-26

No results posted yet for this study

Summary

The goal of this clinical trial is to see if Efavirenz (EFV) intensification to a baseline combination antiretroviral regimen (cART) can help reduce the size of the latent reservoir in people living with HIV (PLWH). The main questions this study aims to address are:

1. is the addition of EFV to a cART regimen safe and well tolerated?
2. Is there a reduction in the blood and tissue HIV reservoir after intensification?

Researchers will compare each participants reservoir size prior to and post EFV intensification.

Conditions

Interventions

DRUG

Efavirenz 600mg

Take One pill daily for 6 months in addition to baseline combination antiretroviral therapy regimen

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2024-12-16
Completion
2024-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07193875 on ClinicalTrials.gov